EVGN — Evogene Ltd.

Summary of Evogene's Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Total revenue for 2025 was approximately $3.9 million, down from $5.6 million in 2024. Q4 2025 revenue was approximately $0.3 million, a decline from $1.5 million in Q4 2024.
• Operating Expenses: Operating expenses decreased significantly to about $13.8 million for the year, compared to $22 million in 2024. Q4 operating expenses were approximately $3.2 million, down from $4.3 million in Q4 2024.
• Net Loss: The net loss for 2025 was approximately $7.8 million, a notable improvement from $18.1 million in 2024. However, Q4 2025 net loss increased to approximately $5.4 million from $5,000 in Q4 2024.
• Cash Position: As of December 31, 2025, Evogene had approximately $13 million in cash. Cash usage in Q4 2025 was about $3 million.

2. Strategic Updates and Business Highlights

• Focus on ChemPass AI: Evogene has streamlined its operations to concentrate on its ChemPass AI platform, which is aimed at generating novel small molecules for drug development and ag chemicals.
• Collaborations: The company is advancing multiple partnered drug discovery programs and has ongoing collaborations with major firms like Google Cloud, Bayer, and Corteva.
• Divestitures: Evogene divested Lavie Bio's majority operations and scaled down Biomica, reallocating resources to enhance its core technology and market focus.

3. Forward Guidance and Outlook

• Evogene aims to become the partner of choice for small molecule discovery and optimization in both pharma and agriculture sectors.
• The company expects to maintain reduced operating expenses and has sufficient cash for at least 1.5 years without additional financing.
• Future catalysts include potential collaborations with larger biotech and chemical companies, which could provide cash inflows.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: The significant drop in revenue from AgPlenus and Casterra, particularly due to reduced seed sales and an inventory impairment of $2.2 million, raises concerns about market demand.
• Increased Operating Loss: Despite reduced expenses, the Q4 operating loss increased, indicating challenges in revenue generation.
• Market Conditions: The agricultural and biotech sectors have faced headwinds, affecting collaboration appetites and overall market performance.

5. Notable Q&A Insights

• BMC128 License Agreement: The agreement with Lishan Pharmaceuticals includes milestone payments and revenue sharing, which could be significant for Evogene.
• Cash from Lavie Bio and Biomica: Expected distributions from these subsidiaries are anticipated to support operations through mid-2026.
• Future Catalysts: Management highlighted three key areas for potential growth: technology collaborations, partnerships with biotech companies, and collaborations with chemical firms, emphasizing a strategic pivot towards innovation and partnerships.

Overall, Evogene is navigating a transformative phase with a clear focus on its AI capabilities while managing financial challenges and market dynamics.